ARTICLE | Clinical News
Ranolazine: Began Phase II trial
January 2, 2001 8:00 AM UTC
CV Therapeutics Inc. (CVTX), Palo Alto, Calif. Product: Ranolazine Business: Cardiovascular Therapeutic category: Metabolism Target: Enoyl-CoA-hydratase Description: Anti-ischemic agent; partial fat...